CTRI/2017/06/008810
Recruiting
Phase 2
Single arm, single centre prospective study to assess the effect of therapeutic drug monitoring (TDM) based dosage adjustment of posaconazole on the incidence of invasive fungal infections (IFIs) in AML patients on induction chemotherapy on posaconazole prophylaxis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Acute Myeloid Leukemia patients started on remission induction chemotherapy
- Sponsor
- Tata Memorial Hospital
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All newly diagnosed AML patients 18 years or above who are started remission induction therapy and started on posaconazole suspension for prophylaxis against invasive fungal infections during induction.
Exclusion Criteria
- •1\)Patients with invasive fungal infections at baseline who are already started on therapeutic doses of antifungals
- •2\)Patients on drugs, that are being taken for control of other comorbidites, that are known to lower the plasma concentrations of posaconazole eg. rifampicin/rifabutin , phenytoin, barbiturates or those drugs known to potentially interact with azole antifungals and cause life threatening adverse events (eg.terfenadine , cisapride, ebastine 24 hours prior to treatment or astemizole 10 days before treatment) (drug interactions with all other concomitant medication will be checked prior to enrolling the patient into the study)
- •3\)Patients with baseline deranged liver function tests at baseline i.e AST/ALT more than 5 times the upper limit of normal or total bilirubin level more than 3 times the upper limit of normal
- •4\)Patients with a previously known hypersensitivity or idiosyncratic reaction to any of the azole antifungals
- •5\)Baseline QTc interval more than 480 milliseconds on ECG
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A study to assess Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2021/03/032072MARC Laboratories Ltd50
Active, not recruiting
Phase 3
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
Not yet recruiting
Phase 4
Clinical study to asses the CT angiography results following the use of the MeRes100 Sirolimus-Eluting Bioresorbable Vascular Scaffold System in patients with coronary artery disease.Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2024/04/066128Dr Keyur Parikh
Active, not recruiting
Phase 1
Study to investigate the performance of a newly developed patch insulin pump in patients with type 2 diabetesType 2 diabetes mellitusMedDRA version: 17.1Level: PTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-004078-40-ATCeQur Corp.
Not yet recruiting
Not Applicable
A prospective, single-centre study to investigate the role of Optical Coherence Tomography and fractional flow reserve for post coronary angioplasty stent optimisatioHealth Condition 1: I208- Other forms of angina pectorisCTRI/2021/04/032543PGIMER